Janssen Search
Search results
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Jun 17, 2024 Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free survival and duration of response ...
Next Frontier in Disease Research That Taps Into the Microbiome
Next Frontier in Disease Research That Taps Into the Microbiome There are trillions of microorganisms living in your gut—and they might just be the key to helping treat diseases like Crohn's disease and ulcerative colitis. Meet a researcher who ...
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Apr 06, 2024 United States Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 ...
Creating Treatments for Infectious Diseases
At Janssen, we have ambitious goals. We strive to discover and develop novel therapeutics and vaccines to treat and cure infectious diseases worldwide, improving treatment outcomes and patients’ lives. Our Fight Against Infectious Diseases Is a Global ...
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Working in partnership with the Pulmonary Hypertension Therapeutic Area team, the Cardiovascular & Metabolism Therapeutic Area is responsible for the discovery research effort in pulmonary arterial hypertension (PAH). ...
Our Commitment to Rheumatology
About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and cartilage erosion lead to irreversible joint damage. 1 Despite advancements in treatments, 20 to 30 percent of ...
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
Oct 16, 2023 United States Three Phase 3 RYBREVANT ® (amivantamab-vmjw) studies (MARIPOSA, MARIPOSA-2 and PAPILLON) in EGFR-mutated lung cancer achieved statistically significant and clinically meaningful progression-free survival endpoints and will ...
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Dec 11, 2023 United States Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including CAR-T Additional presentations ...
Michael Grissinger, MBA
As a member of the Johnson & Johnson organization for more than 20 years, Mike Grissinger, MBA is accountable for the business development activities of the Immunology Therapeutic Area. He offers extensive experience in deals, finance, marketing and ...
Vanessa Broadhurst
VANESSA BROADHURST COMPANY GROUP CHAIRMAN GLOBAL COMMERCIAL STRATEGY ORGANIZATION Vanessa Broadhurst is Company Group Chairman, Global Commercial Strategy Organization (GCSO) and is a member of the Pharmaceuticals Group Operating Committee. Prior to being ...